Sirionbiotech Press Releases

Molecular biologist Dr. Carl Christel to head SIRION Biotech in USA


Molecular biologist Dr. Carl Christel to head SIRION Biotech in USA


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

NOVEMBER 12, 2019

Cambridge, Mass: – SIRION Biotech International Inc., the US subsidiary of German viral technology specialist SIRION Biotech GmbH, has announced that Dr. Carl Christel will head its Cambridge-based North American operations.

Dr. Christel. currently Vice President, US Operations, will relocate to Massachusetts to take up his new role, which will involve expediting SIRION’s gene therapy research & advance drug development in the US market.

Connecting Germany and USA

Dr. Christel has lived and worked as a molecular biologist on both sides of the Atlantic. After receiving his PhD at the Technical University of Munich (TUM), he completed four productive years as postdoctoral fellow at the University of Iowa Carver College of Medicine.

With his well-based understanding of molecular physiology and bilingual background, Carl Christel will be a vital connection between SIRION’s German-based headquarters and the U.S. market, ensuring streamlined global communications.

Client support

In addition, SIRION Biotech international has recruited Dr. Rajesh Panigrahi and Dr. Roman O. Braun, to further support SIRION’s U.S. clients.

Rajesh Panigrahi is an experienced virologist who has devoted more than 10 years of research to investigating the connection between viruses and certain forms of cancer. As a postdoctoral fellow at UMass Medical School in Worcester, Massachusetts, his research was mainly focused on developing the therapeutic EBV vaccine as well as identifying the best AAV vector for the treatment of EBV lymphomas. With his experience in virology, he joined Sanofi as a scientist, where he was involved in the drug development process.

Roman Braun is a scientific leader with broad experience in quantitative research, autoimmunity, cancer, pathogen-host interaction, and vaccine development. He studied in Konstanz, Germany and Bern, Switzerland and graduated with a PhD in Immunology. As a postdoctoral fellow in immunology and vaccine development at the Institute for Virology & Immunology in Bern, Switzerland, he developed novel vaccine formulations and systems biological approaches to understand vaccine response in livestock. Later, at Harvard Medical School and Children’s Hospital in Boston, Massachusetts, Dr. Braun was involved in research to understand inflammatory diseases, cancer, and hematological disorders.

Broadening reach in USA

SIRION Biotech Chief Operating Officer Dieter Lingelbach commented: “We are laser-focused on delivering the world’s most comprehensive viral vector technology platforms to expedite gene therapy research and advance drug development in the U.S. market.”

“With Carl leading our Cambridge office, we’ll be especially well positioned to broaden our reach into the U.S. market, and we welcome Rajesh and Roman to the team and look forward to utilizing their expertise to support our existing customers and further drive our international growth.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Media Contacts

Emmie Twombly, Media Specialist, LaVoieHealthScience
Tel.: +001 (857) 389-6042
Email: etwombly@lavoiehealthscience.com

OR

Dr. Carl Christel, Vice President, Sales & BD, SIRION International Inc.
Tel.: +01 (857) 284 1844
Email: carl@sirion-biotech.de

Resources

Click on Molecular biologist Dr. Carl Christel to head SIRION Biotech in USA for other information.
Click on SIRION to contact the company directly.

Joining SIRION Biotech International, Inc. (left to right): Dr. Roman O. Braun, Dr. Rajesh Panigrahi and Dr. Carl Christel who will head the U.S. office of SIRION Biotech

Joining SIRION Biotech International, Inc. (left to right): Dr. Roman O. Braun, Dr. Rajesh Panigrahi and Dr. Carl Christel who will head the U.S. office of SIRION Biotech


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech participates in combined ABC of AAV offer at ESGCT 2019 Barcelona


SIRION Biotech participates in combined ABC of AAV offer at ESGCT 2019 Barcelona


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

OCTOBER 11, 2019

Martinsried, Germany: – Viral technology specialist SIRION Biotech will be returning to the influential European Society for Gene and Cell Therapy (ESGCT) annual congress to present its ‘ABC of AAV’ offer.

SIRION has attended past ESGCT congresses and will be a prominent presence at the 2019 meeting, to be held in Barcelona as part of the ABC one-stop-shop adeno-associated virus (AAV) for Gene Therapy partnership also involving fellow German companies PROGEN, Genewerk and PlasmidFactory.

ABC of AAV combined experts

The combined ABC of AAV stand at Booths 19-22 at the Barcelona International Convention Center will display the consortium’s combined capabilities in adeno-associated virus engineering and production.

ABC of AAV services offers include safety evaluation, impurity detection, quantification, plasmid manufacture, ITR integrity, particle engineering and quantification, pre-clinical AAV production and GMP manufacturing services.

Advanced gene engineering

The SIRION team in Barcelona will be led by Managing Director and Chief Technology Officer Dr. Christian Thirion and Dr. Sabine Ott, Vice President for Licensing and Business Development.

They will also showcase its impressive portfolio of AAV advances, LentiBOOSTTM lentiviral transduction enhancer, lentiviral vector and adenovirus vector engineering and production capabilities.

“The annual ESGCT congress forms a wonderful platform for increasing our visibility, organizing partnering meetings, networking and getting updated with the latest trends,” commented Dr. Thirion.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

About ESGCT 2019

The European Society of Gene and Cell Therapy (ESGCT) The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology, and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.

The society’s annual congress provides an opportunity for scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. The event currently attracts more than 1,000 delegates from some 40 countries worldwide.

The 20th ESGCT / SETGYC Collaborative Congress (ESGCT 2019), is a four-day event opening October 22 at the Barcelona International Convention Center.

ESGCT 2019 is organised in collaboration with the Spanish Society for Gene and Cell Therapy SETGYC. Further information at: https://www.esgct.eu/Congress/Barcelona-2019.aspx

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH SIRION Biotech
Tel.: +49 89 700 961 9915
Email: Thirion@sirion-biotech.de

Dr. Sabine Ott, VP Licensing & BD, SIRION Biotech
Tel: +49 89 700 961 9919
Email: ott@sirion-biotech.com

Dr. Galiya Sakaeva, Sales & Marketing Manager, SIRION Biotech GmbH
Tel.: +49 89 700 961 9918
Email: sakaeva@sirion-biotech.de

Resources

Click on SIRION Biotech at ESGCT 2019 for other information.
Click on SIRION to contact the company directly.
Click on ABC of AAV to set up meeting at ESGCT Barcelona.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION records 100% revenue growth


SIRION records 100% revenue growth


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

AUGUST 30, 2019

Martinsried, Germany: Leading viral vector technology specialist SIRION Biotech has announced financial results for the first half of 2019 showing record growth.

Gaining momentum from its LentiBoost technology, SIRION experienced 100 percent growth in both the first half of 2019 and the end of the year 2018. The company benefited from the increased demand for its viral vector technologies that enable breakthrough advances in cell and gene therapy.

Service and licensing revenue for the first half of 2019 estimated €6M (US$6.6M).

Rising demand

SIRION’s business model emphasizes service revenue and licensing fees. SIRION provides high-grade viral vector materials for preclinical use, offering up to 10E15 GMP-ready AAV vector genomes and 10E10 infectious units of Lentivirus, paving the way for faster toxicology studies. Additionally, SIRION is seeing rising demand for the technologies that it licenses out.

“We are readying the company for increased demand of our viral vectors, offering the highest quality standards and upscaling capabilities,” commented SIRION Chief Operating Officer Dieter Lingelbach.

Towards US listing

As the company continues its growth strategy, it has completed the TechShare Program with leading pan-European exchange Euronext. The program includes options for a public market listing as a bridge to the company’s eventual goal for a US listing.

“With dedicated staff in Munich, Paris, and Boston, we are committed to supporting our existing customers and further expanding through investment in additional lab infrastructures and technology developments both in Europe and USA,” said Mr. Lingelbach.

Hot topics

“In the third quarter of 2019, SIRION will continue to grow its onsite presence in Massachusetts through its wholly-owned subsidiary, SIRION Biotech International Inc., as it continues to expand into the US market,” he added.

Gene and cell therapy are among the hottest topics in modern drug development. Viral vector technologies are the most promising gene editing tools with significant potential both as therapeutics for a growing number of indication areas and for further technical improvements.

Key challenges include quality, yields, and improved transduction in order to make novel gene therapies reliable and affordable. Costs for gene therapies per patient still come at high price tags, prohibitive for a larger patient population even in well developed markets.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the transformational RNAiONE knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

Media Contacts

Dr. Sabine Ott, VP Licensing & BD, SIRION Biotech
Tel: +49 89 700 961 9919
Email: ott@sirion-biotech.com

Resources

Click on SIRION posts record growth figures for other information.
Click on SIRION to contact the company directly.
Click on SIRION viral vector technologies for further information.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION highlights France as leading force in gene and cell therapy


SIRION highlights France as leading force in gene and cell therapy


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

JUNE 28, 2019

Martinsried, Germany: – Leading viral vector technology specialist SIRION Biotech International (SIRION) has highlighted the growing strength of France as a leading world player in gene and cell therapy.

In an article posted on the SIRION website, the company’s Director for Sales and Business Development, Francois Vromman, points to France’s progress in joining the UK at the top of the world gene therapy league.

SIRION has acknowledged French importance in the sector by strengthening its presence in the country.

Gene therapy clusters

Mr. Vromman points out that France is now home to more than 10 world-leading biotech and research clusters working in gene and cell therapies. Many of these have grown up as the direct or indirect results of pioneering work in genetics, initiated and led by Genethon, which published the first map of the human genome in 1992.

“Their early work put France on the map. Concurrently, the French government decided to promote gene therapy development by facilitating the acceptance of clinical trials, promoting integration of small gene therapy research centers and hospitals encouraging industrial partners to invest in gene therapy programs,” notes Mr. Vromman.

Role of institutions

Thirty years on, the French government is still actively supporting genetic research with Genethon as a leading entity with eight active programs in clinical trials.

“Similarly, Institut Imagine and Institut de la Vision have worked hard to unite researchers, clinicians and industrial partners to drive a large number of French therapies currently under development,” Mr. Vromman says.

“Future involvement by institutions such as the Institut de l’Audition and the Meary Center ensure a future of constant growth spurred on by France’s considerable pool of scientific talent. Further progress comes from cross-regional development initiatives that sponsor academic projects and push proof-of-concept work that is transferred into clinical applications,” he writes.

Out-licensing

On the industry side, several of these innovative academic discoveries have led to out-licensing and collaborations with US-based commercial companies, including adeno-associated virus (AAV) technology developed at Genethon taken up by Novartis US subsidiary Avexis, the creation of GenSight Biologics, a leader in ophthalmology gene therapy, based on work at the Institut de la Vision and sponsorship by US-based Bluebird Bio of pioneering work by Prof. Marina Cavazzana on rare red blood cell disease at Institut Imagine.

Dynamic environment

“The French biotech community continues to boast strong contributors to the development of gene therapy (GenSight Biologics, Vivet Therapeutics, Lysogene) and cell therapy fields (Cellectis, Theravectys, TxCell – now Sangamo Therapeutics), making the French biotech scene a highly fertile environment that will bring competitive therapies to market, promising to secure a good share of the US $35.4 billion gene and cell therapy market,” comments Mr. Vromman.

“At SIRION Biotech, we believe in this leading country and are committed to supporting our partners developing innovative technologies in the field by being at the heart of it with our local office in Paris,” he concludes.

About SIRION Biotech

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

SIRION offerings include the transformational RNAiONE knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

Media Contacts

Dr. Sabine Ott, VP Licensing & BD, SIRION Biotech
Tel: +49 89 700 961 9919
Email: ott@sirion-biotech.com

Resources

Click on SIRION highlights French gene therapy leadership for other information.
Click on SIRION to contact the company directly.
Click on Why France is Leading the Gene and Cell Therapy Field in Europe to see original article.

SIRION Biotech GmbH Director for Sales and Business Development, Francois Vromman

SIRION Biotech GmbH Director for Sales and Business Development, Francois Vromman


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


NIAID allergy institute chooses SIRION LentiBOOST™ technology to strengthen SCID-X1 immunodeficiency study


NIAID allergy institute chooses SIRION LentiBOOST™ technology to strengthen SCID-X1 immunodeficiency study


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

JUNE 25, 2019

Martinsried, Germany: – Leading viral vector technology specialist SIRION Biotech International has concluded a license agreement for its LentiBOOST technology with the US Government’s National Institute of Allergy and Infectious Diseases (NIAID).

NIAID has licensed LentiBOOST to improve clinical efficacy of its hematopoietic stem cell gene therapy programs, and in particular its current study of SCID-X1, the X-linked severe combined immunodeficiency disorder caused by mutations of a single gene, ILR2G.

Threat to children

SCID-X1 causes severe loss of T cells, B cells, and natural killer (NK) cells, leading to profound impairment of the immune system of affected children. Infants born with this severe immune deficiency require a life-saving hematopoietic stem cell transplant in infancy. When the transplant is performed without chemotherapy, most achieve only partial immune reconstitution, continue to have significant chronic medical problems, and also require life-long treatment with monthly injections of supplemental immunoglobulin (antibodies).

Until 2016 there was no treatment to improve the partially functioning immune system and associated medical problems affecting these older children and young adults with SCID-X1. In a clinical study at NIH, a small cohort of these older children and young adult patients with SCID-X1 achieved significant clinical benefits including production of their own immunoglobulins when treated with lentivector gene therapy to express healthy ILR2G. This ongoing study is led by Dr. Suk See De Ravin and Dr. Harry L. Malech of the Genetic Immunotherapy Section in NIAID’s Laboratory of Clinical Immunology and Microbiology.

Boosting transduction efficiency

By use of the LentiBOOST technology, it is NIAID’s expressed goal to achieve a more durable clinical response in SCID-X1 patients receiving this gene therapy. A key element in achieving this is to increase the target level of integrated genome copies for the therapeutic gene into engrafted CD34+ cells. NIAID investigators have found that by including the LentiBOOST technology reagent into their standard GMP transduction manufacturing process, they reliably increased transduction efficiencies many-fold, achieving genome copy numbers of up to 1.5 to 3 copies per cell in the four patients who have been treated recently with cells manufactured with the new transduction method. These early results are highly promising in terms of achieving consistently increased target levels of gene correction.

Applying LentiBOOST across the NIAID portfolio

Following this pilot program, the NIAID will be entitled to apply LentiBOOST technology for early clinical development of its SCID-X1 trial as well as for its complete gene therapy portfolio including multiple stem-cell and T-cell programs.

“Gene therapies stand at a crossroads,” said SIRION Biotech CEO Dr. Christian Thirion.

“Delivery of therapeutic genes by viral vectors is the most critical part of gene and cell therapy approaches nowadays. Our contribution is the optimization of viral vector gene delivery allowing for superior transduction efficiency and long-term gene expression in treated patients. Furthermore, the use of transduction enhancers like LentiBOOST helps to reduce manufacturing costs by lowering the amount of lentiviral vectors needed for production of the cell product,” said Dr. Thirion.

“It fills us with pride to be working with Dr. Malech and Dr. De Ravin at the NIH to improve a promising treatment option for SCID-X1 patients,” he commented.

Tailored licensing model

Dr. Sabine Ott, SIRION VP for Business Development & Licensing, added:

“We have developed a tailored licensing model for research institutions and hospitals providing royalty-free access to its LentiBOOST™ technology and favorable supply conditions for the GMP material for their clinical trials when entirely financed by non-profit sources. LentiBOOST is currently used in several clinical trials in the USA and Europe up to Phase 3 and has proven to be safe and clinically effective.”

About SIRION Biotech

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modelling.

About NIAID

Headquartered at North Bethesda, Maryland, the National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS).

NIAID’s mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases, with in-house laboratories in Maryland and Montana. The institute also funds research conducted by scientists at institutions in the United States and throughout the world and works closely with partners in academia, industry, government, and non-governmental organizations in multifaceted and multidisciplinary efforts to address emerging health challenges such as the pandemic H1N1/09 virus.

NIAID traces its immediate origins to October 1948, when the Rocky Mountain Laboratory and the Biologics Control Laboratory were joined with the NIH Division of Infectious Diseases and Division of Tropical Diseases to form the National Microbiological Institute. In 1955, Congress changed its name to the National Institute of Allergy and Infectious Diseases to reflect the inclusion of allergy and immunology research.

Further information at: https://www.niaid.nih.gov/

Media Contacts

Dieter Lingelbach, COO, SIRION Biotech
Tel: +49 89 700 961 9914
Email: lingelbach@sirion-biotech.com

OR

Dr. Sabine Ott, VP Licensing & BD, SIRION Biotech
Tel: +49 89 700 961 9919
Email: ott@sirion-biotech.com

Resources

Click on SIRION Biotech licenses LentiBOOST to NIAID for other information.
Click on SIRION to contact the company directly.
Click on LentiBOOST for further information.

SIRION’s LentiBOOST™ technology increases levels of integrated genome copies into engrafted CD34+ cells

SIRION’s LentiBOOST™ technology increases levels of integrated genome copies into engrafted CD34+ cells


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech Expands North American Presence by Opening New Site at Cambridge, MA.


SIRION Biotech Expands North American Presence by Opening New Site at Cambridge, MA.


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

MARCH 01, 2019

Martinsried, Germany: – Leading Viral Vector technology specialist SIRION Biotech has significantly expanded its presence in North America with the opening of its new office in Massachusetts as part of the fast expanding Cambridge cluster for genetic and cell therapy research.

The new site will handle business development and liaison between SIRION and its growing number of American partners as part of SIRION’s strategy to expand its profile in the USA.

Gene therapy center of excellence

SIRION formally announced the opening of its new premises at 125 Cambridge park Drive, Suite 301, Cambridge, MA, on February 1, preceded by a Bavarian-style reception and dinner, with guests representing the vibrant Cambridge gene therapy sector. The event also featured addresses from world renowned gene and cell therapy developers and viral vector experts stressing the importance of optimized viral vectors in making gene therapy a reality.

Gene therapy has seen strong clinical advancement, and SIRION is becoming a partner of choice in this growing sector. It recently joined forces with California-based Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases and has also entered collaborations with Orchard Therapeutics, as well as a major public company that is advancing the technology.

Essential viral vectors

Dieter Lingelbach, MD and Chief Operating Officer of SIRION Biotech, commented: “As transduction and manufacturing efficiencies are critical issues in gene therapy, SIRION’s viral vectors are essential to the success of their partnering companies.”

“Since two-thirds of SIRION’s revenue already comes from US customers and partners, opening an office in a Life Science hub like Cambridge, Massachusetts further demonstrates our commitment to supporting existing customers and further expanding into the US market,” Mr. Lingelbach added.

About SIRION Biotech

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

SIRION offerings include the transformational RNAiONE knockdown validation platform along with a full range of virus related services, ranging from particle production to virus driven cell modeling.

Media Contacts

Lisa DeScenza, Assistant Vice President, Integrated Communications
Tel: +1 978 395-5970
Email: ldescenza@lavoiehealthscience.com

OR

Dr. Franziska Ruf; Manager, Key Accounts Europe, SIRION Biotech GmbH
Tel: +49 89 700 961 9928
Email: ruf@sirion-biotech.de

Resources

Click on SIRION Biotech opens Cambridge MA offices for other information.
Click on SIRION to contact the company directly.

The SIRION Biotech Inc. team celebrate their move to Massachusetts with a Grand Opening Reception at the Forsyth Institute in Cambridge. (Photo: Business Wire)

The SIRION Biotech Inc. team celebrate their move to Massachusetts with a Grand Opening Reception at the Forsyth Institute in Cambridge. (Photo: Business Wire)


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech strengthens USA links with new partnership and manufacturing site


SIRION Biotech strengthens USA links with new partnership and manufacturing site


SIRION-BIOTECH 150X64

Press Release | SIRION Biotech GmbH

JANUARY 24, 2019

Martinsried, Germany: – Viral technology specialist SIRION Biotech has significantly expanded its presence in the USA with an important strategic partnership and new site in Massachusetts.

SIRION has joined forces with California-based Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases.

It is also inaugurating a business development and liaison center as part of the Cambridge gene therapy and research cluster.

Focusing on CNS conditions

The license and collaboration agreement with Denali aims to develop gene therapies for diseases of the Central Nervous System (CNS) by developing adeno-associated virus (AAV) vectors to enable therapeutics to cross the blood-brain barrier for clinical applications in neurodegenerative diseases including Parkinson’s, Alzheimer’s disease, ALS and other diseases of the CNS.

The research involves the world-renowned and pioneering scientist in the field of AAV biology, Prof. Dr. Dirk Grimm from the University Hospital Heidelberg (UKHD), who has well-established connections with SIRION.

Combined proprietary technologies

AAV vectors are considered the most promising gene delivery system for therapeutic applications. Denali Therapeutics, SIRION Biotech and Dirk Grimm, will combine proprietary technology platforms to create a next generation of AAV vectors. The goal is to develop new and modified AAV capsids exhibiting a safe product profile with improved specificity and high efficiency for therapeutic drug delivery to the brain.

SIRION founder and CEO Dr. Christian Thirion commented: “This ground-breaking collaboration will help Denali Therapeutics to increase the availability of protein therapeutics in the brain, and to quickly enter clinical trials with efficient, safe and scalable therapeutic candidates.”

New neurodegenerative treatment options

“We believe that through our partnership with Denali, CNS-directed AAV-based gene therapies can reach the market in the fastest possible way, providing novel treatment options to many millions of patients worldwide suffering from devastating neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and ALS,” added Dr. Sabine Ott, SIRION Vice President for BD & Licensing.

Alexander Schuth, COO of Denali Therapeutics said: “We are excited to partner with SIRION Biotech and combine our expertise around the blood-brain barrier and neurodegenerative diseases with SIRION’s leading expertise on viral vectors for gene therapy to enable new treatments for diseases of the brain. This partnership will add a new therapeutic modality to our portfolio and is complementary to our existing biotherapeutic and small molecule programs.”

New Cambridge MA site

At the end of this month, SIRION will also formally inaugurate its new site at Cambridge, Massachusetts, a leading cluster for genetic & cell therapy research, to speed communications between SIRION and its partners in North America. SIRION is being supported in its efforts by CYTO Consulting, who specializes in working with international life science companies to expand commercialization of new technologies into the US market.

The SIRION offices will open with a Bavarian-style reception and dinner on the evening of January 31, featuring addresses from world renowned gene & cell therapy developers and viral vector experts, an open Bavarian buffet and guests representing the range of Cambridge’s innovative gene therapy scene.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing,

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

About Denali Therapeutics

Denali is a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases.

Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development with biomarker monitoring to demonstrate target engagement and select patients. Denali is based in South San Francisco.

For further information, see: www.denalitherapeutics.com.

Media Contacts

Dr. Franziska Ruf; Manager, Key Accounts Europe, SIRION Biotech GmbH
Tel: +49 89 700 961 9928
Email: ruf@sirion-biotech.de

Resources

Click on SIRION Biotech strengthens USA links for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


New success for SIRION Biotech vaccination candidate Ad19a/64


New success for SIRION Biotech vaccination candidate Ad19a/64


Sirion Logo

Press Release | SIRION Biotech GmbH

DECEMBER 12, 2016

Martinsried, Germany: – Viral vector specialist SIRION Biotech’s latest adenovirus serotype Ad19a/64 has reinforced its credentials as a promising vaccination candidate by scoring top marks in a prime boost experiment.

Oncology specialists consider Ad19a/64 to form a promising vaccination and immune oncology tool because it transduces human dendritic cells and myoblasts better than standard adenoviral serotypes.

In October 2016, SIRION reported that using Ad19a to express an antigen had elicited solid immunization in mice, even among animals pre-immunized against common Ad serotypes.

Powerful prime reagent

Now results from a later study have demonstrated that Ad19a/64 vectors can also act as a powerful prime reagent in a two-step prime boost vaccination approach.

In this experiment, animals were first treated with antigen-expressing Ad19a/64. Given alone, this already elicits a solid increase of IFNg and TNFa positive T-cells in the spleen of the animals, indicating immunization. Five weeks after this prime, a secondary boost by DNA vectors was administered. This led to an added increase of marker-positive T-cells by a factor of 20.

POC study

“The synergistic effect of Ad19a/64 combined with a second vector system underline its value as a high potential vaccination candidate to treat a number of yet unmet needs,” said SIRION Biotech CEO, Dr. Christian Thirion.

“Further studies by leading scientific groups are currently being conducted, including a vaccination trial in non-human primates and a proof of concept (POC) study to establish an immune oncology platform,” Dr. Thirion added.

Initial results from the new studies are expected in early January 2017.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational lentiBOOSTTM for high efficiency transduction hematopoietic stem cells and T-cells – even in clinical applications.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo situation. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

Media Contacts

Dr. Carl J. Christel, Senior Manager for Sales and Marketing, SIRION Biotech GmbH
Tel: +49-89-700 961 99-18
Email: christel@sirion-biotech.com

Resources

Click on New success for SIRION Biotech vaccination candidate Ad19a/64 for other information.
Click on SIRION to contact the company directly.
Click on Ad19a/64 for detailed information on new serotype.

Ad19a/64 raises levels of common markers (red circles) beyond immunization threshold. Application of secondary DNA based boost vectors five weeks after the prime increased the effect by a factor 20 (blue squares)..

Ad19a/64 raises levels of common markers (red circles) beyond immunization threshold. Application of secondary DNA based boost vectors five weeks after the prime increased the effect by a factor 20 (blue squares)


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study


SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study


Sirion Logo

Press Release | SIRION Biotech GmbH

OCTOBER 13, 2016

Martinsried, Germany: – Viral technology specialist SIRION Biotech’s latest adenovirus serotype Ad19a/64 has passed a further significant milestone in its validation process as a novel vaccination candidate.

New in vivo results in mice, recorded in a laboratory study conducted by world-renowned researcher Prof. Peter Holst of the University of Copenhagen, have clearly shown that this new serotype elicits comparable immune reactions against a given antigen as effective as Ad5, even in animals that were pre-immunized against the Ad5 serotype.

Adenovirus vectors

“The study underlined the importance of Ad19a/64 development into a vaccination vehicle to solve the problem of pre-immunized populations,” commented SIRION Biotech CEO Dr. Christian Thirion.

“We already knew that pre-immunisation rates against our novel Ad19a/64 are very low in human populations, an important trait for a future vaccination candidate.” he explained.

“But we were not sure whether pre-acquired immunity against the common Ad5 might generate a cross-reaction. This study seems to have removed that uncertainty,” said Dr. Thirion.

HPV clinical testing

As a next step, SIRION Biotech will now enter first pre-clinical testing of the Ad19a/64 vector system in non-human primates to cure human papillomavirus (HPV).

Adenovirus vectors enable the direct introduction of genetic antigen information into patients instead of inoculating them with inactivated pathogen. This method of direct antigen presentation is thought to hold the solution for a number of diseases currently unanswered by standard vaccination methods.

Ad19a/64 has been considered highly promising in this context because it transduces human myoblasts and dendritic cells better than any other serotype.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel.: +49-89-700 961 99-15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study for other information.
Click on SIRION to contact the company directly.
Click on Ad19a/64 for detailed information on new serotype.

Mice were treated with Ad5 or Ad19a/64 vectors carrying the genetic code for a defined antigen as vaccination target. In two groups (Triangles and diamonds) the animals received a round of Ad5 particles before the treatment.  Immunization success 10 days post-application was measured by determining IFNg+ levels in the spleens of all animal groups. Pre-immunization against Ad5 shut down its performance (diamonds), while Ad19a/64 was undisturbed by the pre-immunization event

Mice were treated with Ad5 or Ad19a/64 vectors carrying the genetic code for a defined antigen as vaccination target. In two groups (Triangles and diamonds) the animals received a round of Ad5 particles before the treatment. Immunization success 10 days post-application was measured by determining IFNg+ levels in the spleens of all animal groups. Pre-immunization against Ad5 shut down its performance (diamonds), while Ad19a/64 was undisturbed by the pre-immunization event


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16


SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16


Sirion Logo

Press Release | SIRION Biotech GmbH

OCTOBER 10, 2016

Martinsried, Germany: – Viral technology specialist SIRION Biotech will be returning to ELRIG for its 10th Anniversary Drug Discovery (ELRIG-DD16) conference in Liverpool, UK (October 13th-14th).

The company will be posting its latest insights and advances on its LV, AAV and AV viral vector technologies along with presentations on its advanced vector engineering platform VariCHECK, optimized and re-targeted viral vectors for cell-based therapy as well as research- and clinical grade transduction enhancer LentiBOOSTTM to efficiently transduce primary and hard to target cells.

SIRION’s team will include Dr. Franziska Ruf, Key Accounts Manager for Europe and Dr. Cristina-Ileana Ureche, newly appointed Key Account Manager for Asia.

SIRION is inviting all ELRIG-DD16 delegates to contact the company and set up face-to-face meetings with Dr. Ruf or Dr. Ureche during the conference in Liverpool, UK.

Dr. Franziska Ruf, who will present the poster on VariCHECK, commented:

“Why do I care about viral vectors? Simply because engineered viral vectors are not only perfect tools for functional gene analyses and target research but also transform our understanding of disease, becoming new innovative medicines. ”

“SIRION has been a participant at the ELRIG Drug Discovery conferences for several years now. This is an excellent platform to share our knowledge with fellow scientists and company representatives working in cell based research areas like early drug discovery, gene/cell-based therapy and regenerative medicine ,” said Dr. Ruf.

“We’ll be able to show how in gene therapy we are now achieving the highest LV and AAV T-cell transduction rates on the market and how we are using leading vector engineering and capsid optimization to increase tissue specificity and improve immunogenic profile,” added Dr. Cristina-Ileana Ureche.

About SIRION Biotech

In business since 2007 and based near Munich in Germany, SIRION BIOTECH is Europe’s leading commercial supplier of tailored viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

SIRION’s mission is to change the paradigm for viral vector supplies, with its ability to develop and supply all common viral vector types (adenovirus, lentivirus and AAV) in highest quality within a matter of weeks.

The company also offers a full range of virus related products and services, ranging from transduction enhancer agents to fully customized cell models including the transformative RNAiONE™ knockdown validation platform.

With this comprehensive viral vector portfolio, SIRION offers a suitable option for almost any preclinical in vitro and in vivo application.

About ELRIG DD16

The European Laboratory Research & Innovation Group (ELRIG) is a UK-based not-for-profit organization serving the needs of the drug discovery and life science communities across Europe. ELRIG’s flagship event, “Drug Discovery” now attracts more than 1,300 delegates, making it the biggest conference of its kind in Europe.

The 10th anniversary Drug Discovery ’16 is a two-day event, opening October 13 at the Echo Arena (ACC) in Liverpool. The conference will feature more than 50 speakers over six session tracks focusing on Innovations in Chemistry, Oncology & Immunology, Innovations in Predictive & Translational Models, Assay Development, Screening & Emerging Technologies, Cells and Genes in Therapy and Diagnostics and Target Identification & Validation. The conference will also feature an exhibition, as well as a new feature, interactive Core Technologies Workshops & Vendor Tutorials.

More information at: http://elrig.org/portfolio/drug-discovery-2016/

Media Contacts

Dr. Franziska Ruf; Manager, Key Accounts Europe, SIRION Biotech GmbH
Email: ruf@sirion-biotech.de

Resources

Click on SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16 for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume


SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume


Sirion Logo

Press Release | SIRION Biotech GmbH

JULY 19, 2016

Martinsried, Germany: – German publisher Springer Protocols has issued volume on lentiviral vector (LV) protocols for gene engineering that also includes innovative advances made by Munich-based SIRION Biotech.

The latest volume in the Springer series on ‘Methods in Molecular Biology’ addresses “Lentiviral Vectors and Exosomes as Gene and Protein Tools” in which leading scientists in the field of gene editing describe novel approaches based on lentivirus technology.

In the new volume, Maurizio Federico of the National AIDS Center in Rome, Italy, presents 19 such approaches ranging from LV construction over LV targets and applications over integrase-mutant LV’s to the engineering of exosomes.

Moving to industrial applications

Contributors also include Axel Schambach of Hannover Medical School, and David Fenard of French Généthon in Evry and Natasa Anastasov at Munich’s Helmholtz Center of Radiation Biology.

Also described are new lentiviral transduction methods using poloxamers as reagents, spinoculation and scFv-antibody fusions to VSV-G that increase viral performance more than tenfold, with the potential to improve clinical protocols.

SIRION Biotech is a pioneer in customizing Lentivirus to enhance their application spectrum in research and development. Hundreds of viral vector based methods are in or on the verge of clinical testing, making this relatively new class of biologicals as exciting and promising as antibody technologies 30 years ago.

About SIRION Biotech
SIRION Biotech was founded at Martinsried, near Munich, in 2007, with the vision of developing next generation viral vectors for gene therapy and vaccines and enabling the creation of novel cell models closer to reality than ever before. This required the assembly of a comprehensive viral vector platform.

Since then, SIRION has become an international leader in innovating virus vector technologies, providing custom services to academic and industrial partners worldwide. Its core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application.

SIRION is now Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies. It is also the only company to master all three major virus types that are used regularly for genetic manipulation of cell systems: all-in-one Lentivirus, adeno-associated viruses (AAVs) and Adenovirus vectors.

SIRION’s technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel: +49 89 700 961 99 15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume for other information.
Click on SIRION to contact the company directly.
Click on Lentiviral Vectors to see abstract of the volume.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech expands business and ideas


SIRION Biotech expands business and ideas


Sirion Logo

Press Release | SIRION Biotech GmbH

FEBRUARY 23, 2016

Munich, Germany: – Viral technology specialist SIRION Biotech has reported revenues almost doubled during the last financial year as well as major new collaboration and licensing deals.

These developments consolidate SIRION’s pole position as a leading force in gene delivery technologies and hi-tech developer of viral vector technologies, catering to the life sciences.

During the second half of 2015, SIRION Biotech concluded landmark deals with global pharma companies to develop and license next-generation gene delivery techniques.

Moving to industrial applications

These deals all reflect growing interest in novel therapies and vaccines that use viral gene delivery tools as bases for curative therapies.

“The company has entered new territory by also specializing in industrial uses of its technologies, in addition to drug discovery and early R&D applications,” commented SIRION Biotech’s Managing Director, Dieter Lingelbach.

“The fact that we struck major deals in both sectors last year means that virus-based delivery is in the process of becoming a routine commercial application, very much like antibodies did about 20-30 years ago,” added Mr. Lingelbach.

Collaborative partnerships

As specialists for the design and engineering of viral vectors SIRION Biotech will collaborate closely with its Pharma- and Biotech-partners to engineer specific gene delivery systems to accurately fit in the context of their therapeutic developments. The projects will be built from a preclinical base upwards, maintaining active collaboration well into the clinical phases.

“With SIRION at their sides, our partner companies will be able predict and address the roadblocks laid out by the complex nature of modern gene applications and take these hurdles in stride,” said Dr. Carl J. Christel, SIRION’s Senior Manager of Sales & Marketing.

“In the end this joint approach will help create and refine new technologies to be implemented in a wide array of gene replacement therapies, cancer immunotherapies and genetic vaccination approaches,” says Dr. Christel.

Expanding research boundaries

SIRION has also turned to a form of crowd sourcing to influence its future development pipeline.

With a whole list of AAV engineering projects for 2016, SIRION is pushing the boundaries of in-vivo gene modification to enable highest possible expression control.

Now it has appealed for ideas from partners and researchers visiting its website for their ideas as to which tissue or cell types are the most interesting research candidates to be included in its R&D program.

“This is your chance to influence our AAV program.” the company says.

The current SIRION AAV-R&D pipeline includes optimized AAV serotypes to target specific cell types and tissues, including endothelial AAV, inducible AAV expression vectors and AAV transduction boosters to maximize transduction efficiencies.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become an international leader in innovating virus vector technologies, providing custom services to academic and industrial partners worldwide. Its core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application.

SIRION is now Europe’s leading supplier of viral vectors used for genetic research, target validation, gene therapy and vaccination studies. It is also the only company to master all three major virus types that are used regularly for genetic manipulation of cell systems: All-in-one Lentivirus, adeno-associated viruses (AAVs) and adenovirus vectors.

SIRION offers a range of advanced technologies including control gene expression and knockdown, inducible, tissue specific expression and transduction boosters, as well as a full range of virus related services, ranging from particle production to virus driven cell modeling.

Media Contacts

Dr. Carl J. Christel, Sales & Marketing, SIRION Biotech GmbH
Tel: +49 89 700 961 99 18 (Europe)
Tel: +1 857 284 1844 (North America)
Email: christel@sirion-biotech.com

Resources

Click on SIRION Biotech expands business and ideas for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech announces preclinical vaccination success


SIRION Biotech announces preclinical vaccination success


Sirion Logo

Press Release | SIRION Biotech GmbH

JANUARY 11, 2016

Martinsried, Germany: – Viral technology specialist SIRION Biotech has opened the New Year by announcing its first successful preclinical vaccination results from ProVector™ cell products, clearing a pathway to future clinical applications.

SIRION has used its new ProVector™ cell line to increase production of demanding virus constructs, successfully engineering and producing new vaccination vectors based on the adenoviral serotype Ad19a.

The company has collaborated with Prof. Peter J. Holst of the Novo Nordisk Foundation for Basic Metabolic Research at University of Copenhagen to test these new vaccination vectors in rodents.

Outstanding T-cell activation

“Results rose above all expectations,” said SIRION Biotech CEO Dr. Christian Thirion.

“T-cell activation showed an increase against pathogen antigen that not only matched but exceeded responses generated with standard vector systems,” Dr. Thirion explained.

“These promising results lay the groundwork for development of the Ad19a system as the newest openly available vector platform for vaccination R&D. Providing similar results in the next animal system, first clinical applications may be expected as soon as 2017,” he added.

Viral vector technologies

Traditional vaccines are built from inactive or attenuated elements of a pathogen. Viral vectors on the other hand work as DNA or RNA transporters to reprogram a patient’s cells in order to produce a particular antigen and present it directly to the immune system.

This method favors a cell-mediated immune response that fortifies the vaccination success. It also increases the medical potential as it can help fight established disease or cancers as a new form of therapy, on top of serving as a preventative measure.

From a commercial standpoint, viral vectors can help eliminate complex manufacturing processes of classic vaccines and avoid secondary and tertiary structural deviations that are common in synthetic antigen production.

AD19a: preventative vaccination hopes

Ad19a is the latest in adenoviral (AV) gene vector innovations. Demonstrating its ability to elicit robust immune response against a genetically coded antigen in a rodent model, together with a new production cell line that caters to special requirements of complex gene vectors, addresses several challenges of modern vaccination R&D. Hopes are high that it will pave the way to create preventative vaccinations as well as new cancer therapies that will benefit a big segment of the population.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel: +49-89-700 961 99-15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech announces preclinical vaccination success for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/


SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe


SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe


Sirion logo

Press Release | SIRION Biotech GmbH

OCTOBER 29, 2015

Martinsried, Germany: – Viral technology specialist SIRION Biotech will bring details of its breakthrough vaccines to November’s prestige BIO-Europe biotechnology partnering conference in Munich.

The SIRION team, led by CEO Dr. Christian Thirion, will show how its new production cell lines have managed to produce high yields of its novel DNA viral vectors associated with toxic antigens, which have hitherto been difficult to express.

Breakthrough vaccines

“We believe our work means that very soon will there be novel breakthrough vaccines in the market,” said. Dr. Thirion.

“Associating vaccines with just prophylaxis will soon be a paradigm of the past. Increasingly, vaccines will demonstrate therapeutic effects specifically in the field of so far difficult to address tumor diseases and immune therapies,” he commented.

HEK293 genetic modification

A critical hurdle has in the past been making enough of the vaccine vector material. This is especially difficult when the viral or bacterial origin of antigens makes them potentially toxic, as is the case with the majority of HIV envelope proteins and bacterial virulence factors.

Over a two-year development project, SIRION Biotech has applied genetic modification to widespread and inexpensive HEK293 cells to suppress specific antigen production. This novel cell line overcomes production issues related to all DNA-based viral vectors that express toxic proteins during the process. The technology is generally applicable to the production of DNA-vector based vaccines and can be applied to common vaccine production cell lines.

Cancer immune therapies

SIRION Biotech has combined its new antigens with innovative invariant chain adjuvant technology developed by Prof. Peter Holst of University of Copenhagen in the quest for novel cancer immune therapies.

The co-development has been based on SIRION’s lead candidate Ad19a as novel adenovirus serotype with promising immune response-stimulating activity. A preclinical safety and efficacy study will soon evaluate a treatment vaccine based on this technology against established HPV infections.

About SIRION Biotech

Founded at Martinsried, near Munich, in 2007, SIRION BIOTECH has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.

From the beginning, SIRION’s mission has been to change the paradigm for viral vector supplies, with ability to develop and supply all common viral vector types (adenovirus, lentivirus, AAV, etc.) within a matter of weeks at the concentration titers and quantities needed for preclinical human and animal testing.

The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling.

SIRION offerings include the transformational RNAiONE™ knockdown validation platform.

SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. SIRION can supply all three of the most commonly used virus systems for gene manipulation: recombinant adenovirus particles (AVs), lentiviruses and adeno-associated viruses (AAVs).

About BIO-Europe 2015

The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2015 event is a three-day event opening November 2 at Munich’s ICM international conference center.

BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

Partnering at BIO-Europe 2015 is powered by EBD Group’s partnering ONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

More information at: www.ebdgroup.com/bioeurope/index.php

Media Contacts

Dr. Christian Thirion, CEO, SIRION Biotech GmbH
Tel: +49-89-700 961 99-15
Email: thirion@sirion-biotech.com

Resources

Click on SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe for other information.
Click on SIRION to contact the company directly.


Supplier Information
Supplier: SIRION Biotech GmbH
Address: Am Klopferspitz 19, 82152 Martinsried, Germany
Tel: +49 89 700 961 99 9
Fax: +49 89 700 961 99 8
Website: http://www.sirion-biotech.com/